Table 2 Univariate and multivariate analyses of 34 antibodies for DFS

AF6

Neg.

193 (23%)

Pos.

656 (77%)

0.86 (0.63 to 1.20)

0.386

0.87 (0.61 to 1.24)

0.437

Angiogenin

Neg.

71 (7%)

Pos.

879 (93%)

1.06 (0.65 to 1.74)

0.803

1.01 (0.59 to 1.75)

0.967

Aurora A

Neg.

585 68%)

Pos.

276 (32%)

1.41 (1.07 to 1.87)

0.015

1.32 (0.98 to 1.79)

0.070

BCL2

Neg.

377 (39%)

Pos.

580 (61%)

0.60 (0.47 to 0.78)

<.001

0.82 (0.60 to 1.12)

0.217

α-Catenin

Neg.

359 42%)

Pos.

501 (58%)

0.88 (0.67 to 1.16)

0.374

0.99 (0.73 to 1.34)

0.927

β-Catenin

Neg.

265 (29%)

Pos.

636 (71%)

0.83 (0.63 to 1.11)

0.216

0.88 (0.64 to 1.21)

0.439

CAV1

Neg.

179 (19%)

Pos.

778 (81%)

1.39 (0.96 to 1.99)

0.077

1.16 (0.76 to 1.76)

0.495

CD10

Neg.

409 (45%)

Pos.

508 (55%)

1.19 (0.91 to 1.55)

0.199

1.20 (0.90 to 1.61)

0.211

CD44

Neg.

430 (61%)

Pos.

280 (39%)

0.83 (0.62 to 1.14)

0.264

0.90 (0.65 to 1.25)

0.524

CK5/6

Neg.

248 (27%)

Pos.

667 (73%)

0.88 (0.67 to 1.18)

0.414

0.98 (0.71 to 1.36)

0.921

CK8/18

Neg.

22 (2%)

Pos.

948 (98%)

0.30 (0.17 to 0.55)

<.001

0.54 (0.28 to 1.03)

0.060

CK14

Neg.

774 (83%)

Pos.

158 (17%)

1.01 (0.71 to 1.42)

0.974

0.81 (0.55 to 1.19)

0.288

Cyclin D1

Neg.

316 (33%)

Pos.

648 (67%)

0.86 (0.66 to 1.13)

0.301

1.11 (0.81 to 1.51)

0.526

E-Cadherin

Neg.

128 (13%)

Pos.

873 (87%)

1.09 (0.74-1.60)

0.653

0.98 (0.62-1.57)

0.937

EGFR

Neg.

814 (81%)

Pos.

185 (19%)

1.02 (0.74 to 1.41)

0.895

0.72 (0.49 to 1.05)

0.090

ER

Neg.

283 (26%)

Pos.

785 (74%)

0.53 (0.42 to 0.69)

<0.001

0.90 (0.47 to 1.71)

0.744

FGFR1

Neg.

114 (15%)

Pos.

626 (85%)

1.36 (0.86 to 2.14)

0.189

1.60 (0.93 to 2.74)

0.087

FHIT

Neg.

237 (26%)

Pos.

672(74%)

1.03 (0.76 to 1.40)

0.825

1.41 (0.98 to 2.01)

0.062

GATA3

Neg.

166 (17%)

Pos.

816 (83%)

0.70 (0.52 to 0.96)

0.027

0.83 (0.58 to 1.19)

0.311

HER2

Neg.

917 (84%)

Pos.

175 (16%)

1.64 (1.23 to 2.19)

<0.001

1.12 (0.80 to 1.57)

0.493

Ki67

Neg.

661 (70%)

Pos.

280 (30%)

1.97 (1.51 to 2.56)

<0.001

1.53 (1.12 to 2.08)

0.007

MET

Neg.

602 (66%)

Pos.

315 (34%)

1.26 (0.97 to 1.65)

0.088

1.25 (0.93 to 1.66)

0.134

Moesin

Neg.

824 (87%)

Pos.

118 (13%)

1.31 (0.91 to 1.89)

0.145

1.95 (.63 to 1.44)

0.815

MUC1

Neg.

95 (9%)

Pos.

938 (91%)

0.59 (0.42 to 0.86)

0.005

0.77 (0.51 to 1.16)

0.213

P21

Neg.

378 (41%)

Pos.

545 (59%)

0.93 (0.71 to 1.22)

0.616

0.84 (0.62 to 1.13)

0.241

P27

Neg.

175 (19%)

Pos.

768 (81%)

0.89 (0.65 to 1.24)

0.509

1.06 (0.75 to 1.50)

0.754

P53

Neg.

746 (75%)

Pos.

246 (25%)

1.59 (1.21 to 2.07)

<.001

1.29 (0.95 to 1.75)

0.107

P-Cadherin

Neg.

570 (61%)

Pos.

371 (39%)

1.44 (1.12 to 1.87)

0.005

1.31 (0.96 to 1.78)

0.089

PR

Neg.

488 (46%)

Pos.

581 (54%)

0.54 (0.42 to 0.69)

<0.001

0.66 (0.47 to 0.92)

0.013

PTEN

Neg.

314 (34%)

Pos.

610 (66%)

1.00 (0.76 to 1.33)

0.977

1.00 (0.74 to 1.36)

0.991

TACC2

Neg.

148 (17%)

Pos.

723 (83%)

1.05 (0.73 to 1.52)

0.777

0.95 (0.64 to 1.42)

0.796

TACC3

Neg.

35 (6%)

Pos.

564 (94%)

1.83 (0.75 to 4.47)

0.179

1.17 (0.47 to 2.88)

0.738

TAU

Neg.

685 (83%)

Pos.

141 (17%)

0.56 (0.36 to 0.88)

0.011

0.75 (0.47 to 1.21)

0.243

TOPO2A

Neg.

199 (22%)

Pos.

714 (78%)

1.41 (0.99 to 2.00)

0.052

1.39 (0.93 to 2.07)

0.104